28.07.2023 • News

Roquette to Acquire Qualicaps

French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.

The transaction is expected to close in the fourth quarter of 2023 but remains subject to the fulfillment of some customary and legal conditions. Financial details were not disclosed.

Qualicaps, part of Mitsubishi Chemical, is headquartered in Nara, Japan, and is the third largest producer of hard capsules for oral dosage solutions. The company has 1,400 employees located in sites in Asia, Europe and the Americas, and its client base includes major pharmaceutical and food companies around the world.

Roquette commented that this strategic investment offers the ability to expand the global footprint of its pharmaceutical business, as well as enrich its offerings of oral dosage solutions.

The newly combined businesses will offer the most diverse range of oral dosage solutions to existing and new customers, said Roquette.

Pierre Courduroux, CEO of Roquette, said: “Today’s announcement is a significant step in Roquette’s journey to reinforce its position as a key player in Health and Nutrition markets. Qualicaps’ strong position in hard capsules will represent a significant addition to our excipients’ portfolio and will enable our company to offer more solutions responding to the needs of our customers and to the demands of patients who are looking for continuously better treatments.”

Roquette has agreed to acquire Qualicaps, a producer of hard capsules and...
Roquette has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage. © Roquette

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read